Central Texas Neurology Consultants   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Round Rock TX United States (1992)

Organization Overview

First Clinical Trial
2005
NCT00109161
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Central Texas Neurology

Active Ingredients

Drugs in Phase 3 Trials (1)

alemtuzumab (campath) (1 trial)

Drugs in Phase 2 Trials (3)

daclizumab (Zenapax) (1 trial)

tovaxin (2 trials)

ublituximab (Briumvi) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 3)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial APIs: 4